F-Prime Capital

Founded in 1969, F-Prime Capital is a venture capital firm based in Cambridge, Massachusetts. It invests globally in technology and healthcare sectors, supporting entrepreneurs with its extensive domain expertise and relationships.

Abdul Abdirahman

Senior Associate

Sanjay Aggarwal

Partner

Jessica Alston

Partner

Nikhil Ananth

Associate

Hannah Arnold

Principal

Ben Auspitz

Partner

Raj Basak

Associate

Sam Bisbee

Venture Partner

Eric Blatte

Venture Partner

Carl Byers

Partner

Amber Cai

Venture Partner

Kevin Chu

Principal

Brett Cook

Principal

Jay Farber

Venture Partner

Shervin Ghaemmagham

Operating Partner

Shervin Ghaemmaghami

Partner

Benjamin Gorman

Venture Partner

David Jegen

Managing Partner

Stephen Knight MD

Managing Partner

Sarah Lamont

Senior Associate

Erica Lee

Associate

Connie Li

Senior Associate

Jonathan Lim

Partner

John Lin

Principal

Muzammil Mansuri Ph.D

Venture Partner

Julia McDowell

Venture Partner

Betsy Mulé

Associate

Sandor Palfy

Venture Partner

Ketan Patel

Partner

Sachin Patodia

Partner

Cameron Raglin

Associate

John Raguin

Venture Partner

Brett Rome

Venture Partner

Steve Schultz

Venture Partner

Mihir Shah

Venture Partner

Siyu Shi Ph.D

Associate

Nihal Sinha

Partner

Anastasiya Sybirna

Senior Associate

Martin Taylor

Senior Associate

Gaurav Tuli

Partner

Jennifer Uhrig

Senior Managing Director

Mona Vernon

Venture Partner

Robert Weisskoff

Partner

Stacie Weninger Ph.D

President, FBRI

M. Jackson Wilkinson

Venture Partner and Operating Partner

Alex Wong

Associate

Rocio Wu

Principal

Chong Xu

Partner

Brian Yordy

Senior Associate

Tristan Zajonc

Venture Partner

Michael Zheng

Venture Partner

Past deals in Health Care

Bluebird Kids Health

Series A in 2025
Bluebird Kids Health is a pediatric healthcare provider that aims to build a healthier future for children. It offers a value-based care model, delivering comprehensive, evidence-based care tailored to each family's needs. Services include nutrition support, sleep training, treatments for common ailments like rashes and viruses, all aimed at reducing medical costs and providing personalized care. The company is also developing a proprietary technology platform, enhanced by AI, to proactively manage and coordinate treatment, further simplifying the experience for its clinical team.

HiLabs

Series B in 2024
HiLabs is a developer of a healthcare data mining platform that aims to enhance data-driven decision-making within healthcare organizations. By leveraging artificial intelligence, HiLabs empowers employees to explore their data intuitively, uncover novel insights, and interact with data visualizations. The platform allows users to customize dashboards and generate new attributes, thus enhancing their ability to understand and utilize client health data effectively. HiLabs recognizes that healthcare providers possess vital domain knowledge but often lack the necessary tools to extract meaningful insights from their data. Through its innovative solutions, HiLabs bridges this gap, enabling healthcare organizations to harness their data more efficiently and improve overall decision-making processes.

Devoted Health

Series E in 2023
Founded in 2017, Devoted Health is dedicated to enhancing the health and well-being of older Americans by offering integrated Medicare Advantage plans. They provide personalized care through a combination of local providers, virtual and in-home care, dedicated guides, and advanced technology.

Pulmocide

Series C in 2022
Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Firefly Health

Venture Round in 2022
Founded in 2016, Firefly Health delivers AI-driven virtual-first primary care. Its platform connects patients with healthcare professionals for convenient, continuous care, focusing on common conditions and women's health issues.

Invetx

Series B in 2022
Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, specializing in the development of protein-based therapeutics for animal health care and veterinary medicine. The company employs a team of veterinary scientists and clinicians dedicated to the discovery and development of biotherapeutics for both pets and farm animals. Invetx aims to transform the animal health industry by leveraging biopharmaceutical technologies to improve health outcomes significantly. By combining deep expertise in veterinary science with innovative therapeutic solutions, Invetx seeks to advance the future of animal care, providing effective treatments that cater to the needs of various animal populations.

Leyden Labs

Series B in 2022
Leyden Labs develops a Mucosal Protection Platform to protect against respiratory viruses, including influenza and coronaviruses. The company offers a portfolio of broad protective nasal sprays designed to reduce the risk of infection and limit transmission, aiming to improve public health through innovative protection methods. Its team combines biotechnology veterans with new talent to advance solutions that address common viral threats at the mucosal surface.

Patina

Series A in 2021
Patina is a healthcare company reinventing primary care for older adults by delivering a human, personalized, on-demand care model designed to improve the healthcare and aging experience for seniors and their families. The approach centers on the specific needs and values of aging individuals, offering flexible access to care and enabling families and loved ones to participate as part of the care team. By focusing on dignity in aging and a coordinated, person-centered experience, Patina aims to align medical care with daily living and the goals of aging adults.

Stride Health

Series C in 2021
Stride Health, Inc. is a health benefits platform that specializes in providing affordable health coverage options for independent workers and part-time employees in the United States. The company offers a range of services, including dental plans, doctor and prescription insurance plans, and various health coverage options tailored to meet the needs of its customers. Stride Health simplifies the enrollment process by guiding users through selecting the most cost-effective health plans, aiming to optimize their tax benefits and enhance their take-home pay. Founded in 2013 and based in San Francisco, California, the company was previously known as Covered, Inc. and rebranded to Stride Health, Inc. in March 2013. Stride Health also provides personal advisory services to assist clients in navigating the complexities of their health insurance options.

Carrot Fertility

Series C in 2021
Carrot Fertility, Inc. offers comprehensive fertility benefits services for employers, supporting employees throughout their fertility healthcare journey on a global scale. Founded in 2015 and headquartered in San Francisco, California, the company provides a range of services including egg freezing, in vitro fertilization, adoption, donor and gestational carrier services. It also features Carrot Rx, a premium pharmacy experience for fertility medications, and Carrot Pregnancy, which offers virtual access to experts and on-demand doctor-approved content. Additionally, Carrot Card is a flexible debit card that employees can use to pay for fertility care. Carrot Fertility aims to help companies customize their fertility benefits, ensuring that employees receive the necessary financial, medical, and emotional support as they pursue parenthood. The company has expanded its presence with additional offices in major cities including Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.

Orient Speech Therapy

Series C in 2021
Orient Speech Therapy Center specializes in providing professional speech and language therapy services for children facing communication challenges, including those with autism or speech disorders. The center focuses on the early screening, clinical diagnosis, and therapeutic interventions essential for improving children's speech and social skills. It offers a range of refined curricula designed specifically for young learners, including the Star Curriculum, phonics and oral muscle courses, expression courses, and exercise classes. Through these structured programs, Orient Speech Therapy Center aims to enhance the communicative abilities of children, enabling them to express themselves more effectively and engage socially.

Pulmocide

Series C in 2021
Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Firefly Health

Series B in 2021
Founded in 2016, Firefly Health delivers AI-driven virtual-first primary care. Its platform connects patients with healthcare professionals for convenient, continuous care, focusing on common conditions and women's health issues.

Leyden Labs

Series A in 2021
Leyden Labs develops a Mucosal Protection Platform to protect against respiratory viruses, including influenza and coronaviruses. The company offers a portfolio of broad protective nasal sprays designed to reduce the risk of infection and limit transmission, aiming to improve public health through innovative protection methods. Its team combines biotechnology veterans with new talent to advance solutions that address common viral threats at the mucosal surface.

Cohort

Series B in 2021
Cohort, Inc. is a software company focused on enhancing chronic care management and clinical trial processes. Based in New York with an additional office in San Francisco, the company utilizes clinical artificial intelligence and natural language processing to analyze electronic health records. This analysis includes evaluating diagnostics, medications, and clinical notes to provide context relevant to specific patients and their conditions. Cohort’s software streamlines the identification and enrollment of eligible patients, generates tailored care plans, and automates compliance and billing tasks. The company’s solutions are designed to enable Primary Care Providers to improve the scale, efficiency, and outcomes of their Chronic Care Management programs while facilitating clinical trial identification and enrollment.

J-Pharma

Series D in 2021
J-Pharma specializes in developing novel pharmaceuticals based on a human-genomic approach. Its intellectual property focuses on cell membrane transporters linked to various diseases, enabling the creation of targeted drugs and diagnostic methods. The company aims to improve global health and enhance quality of life for aging populations by generating new drug agents.

Carrot Fertility

Series B in 2020
Carrot Fertility, Inc. offers comprehensive fertility benefits services for employers, supporting employees throughout their fertility healthcare journey on a global scale. Founded in 2015 and headquartered in San Francisco, California, the company provides a range of services including egg freezing, in vitro fertilization, adoption, donor and gestational carrier services. It also features Carrot Rx, a premium pharmacy experience for fertility medications, and Carrot Pregnancy, which offers virtual access to experts and on-demand doctor-approved content. Additionally, Carrot Card is a flexible debit card that employees can use to pay for fertility care. Carrot Fertility aims to help companies customize their fertility benefits, ensuring that employees receive the necessary financial, medical, and emotional support as they pursue parenthood. The company has expanded its presence with additional offices in major cities including Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.

PatientPing

Series C in 2020
PatientPing, Inc. is a health technology company that has developed a national care coordination network aimed at enhancing communication among healthcare providers. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers real-time notifications and care guidelines to various healthcare professionals, including physicians, nurses, case managers, and care coordinators. This network spans hospitals, emergency departments, accountable care organizations, physician practices, skilled nursing facilities, home health agencies, and payers. PatientPing's platform includes a tool called Spotlights, which leverages real-time data to analyze utilization and performance trends in patient care. By improving information sharing among care teams, PatientPing facilitates higher quality, cost-effective care, ultimately aiming to enhance patient outcomes and experiences. The company also maintains a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC.

NFlection Therapeutics

Series A in 2020
NFlection Therapeutics, Inc. is a biotechnology company dedicated to discovering and developing targeted therapies for rare disorders, particularly focusing on neurofibromatosis type 1 and related conditions. The company specializes in addressing diseases driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway, including cutaneous neurofibromas and other conditions such as immunosuppressant-mediated squamous cell carcinoma and congenital birthmarks. NFlection Therapeutics is known for its innovative approach to drug formulation, offering treatments in a cosmetically elegant gel that can be applied topically, allowing for localized suppression of the Ras pathway while minimizing systemic side effects associated with oral medications. Established in 2014, the company is headquartered in Wayne, Pennsylvania.

Rallybio

Series B in 2020
Rallybio is a clinical-stage biopharmaceutical company focused on developing therapies for severe and rare diseases. Its programs cover hematology, immuno-inflammation, maternal-fetal health and metabolic disorders, with a lead candidate aimed at preventing fetal and neonatal alloimmune thrombocytopenia, a life-threatening condition that can cause bleeding in fetuses and newborns. Founded in 2018 and based in New Haven, Connecticut, Rallybio develops therapies across antibodies, small molecules and engineered proteins to address unmet needs in rare diseases. Guided by experienced biopharma leadership, the company emphasizes translating biology into transformative therapies for underserved patients.

Devoted Health

Series C in 2020
Founded in 2017, Devoted Health is dedicated to enhancing the health and well-being of older Americans by offering integrated Medicare Advantage plans. They provide personalized care through a combination of local providers, virtual and in-home care, dedicated guides, and advanced technology.

Iora Health

Series F in 2020
Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Firefly Health

Series A in 2019
Founded in 2016, Firefly Health delivers AI-driven virtual-first primary care. Its platform connects patients with healthcare professionals for convenient, continuous care, focusing on common conditions and women's health issues.

Buoy Health

Series B in 2019
Buoy Health is a health technology company that develops AI-powered digital health tools to help individuals manage healthcare options. It offers an online healthcare assistant that analyzes symptoms, performs first-line triage, and provides treatment recommendations. Its platform delivers real-time symptom analysis and helps users navigate the healthcare system, research benefits, and locate in-network providers. For employers, the platform surfaces benefits information, guides employees to in-network providers, and integrates with other health portals. Founded in 2014 and based in Boston, Buoy Health aims to resemble a physician-patient conversation through machine learning and proprietary data, enabling users to make informed care decisions.

Structure Therapeutics

Series A in 2019
Structure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule medicines for chronic diseases with high unmet medical needs. Its platform combines structure-based drug design, computational chemistry, and data integration to create orally available therapies that overcome limitations of biologics and peptide drugs. The company concentrates on targeting G-protein coupled receptors and other mechanisms, leveraging structural insights to identify differentiated, efficacious, and safe treatments. Its programs address cardiovascular, metabolic, and pulmonary conditions, with a focus on delivering convenient, effective medicines that can offer broad patient impact and commercial potential. Structure Therapeutics conducts its research and development activities across its pipeline within a single organization and seeks to advance clinical candidates through development.

Nebula Genomics

Series A in 2018
Nebula Genomics is a biotechnology company founded in 2016 and based in San Francisco, California. It specializes in human genome sequencing and the creation of a marketplace for genomic and health data aimed at consumers, researchers, and the medical community. The company's mission is to facilitate genomic sequencing and enhance personalized medicine by aggregating a substantial repository of genetic information. Utilizing blockchain technology, Nebula Genomics ensures that consumers retain control over their data and receive compensation for its use. The marketplace enables researchers to analyze rich genetic datasets, which can accelerate drug development and improve the efficiency of clinical trials. Founded by prominent genomics researcher George Church and his associates, Nebula Genomics offers advanced DNA sequencing technology that allows clients to explore all genes and genetic variants in the genome, thereby providing comprehensive insights into individual health.

Iora Health

Series E in 2018
Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Kyruus

Corporate Round in 2018
Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Nebula Genomics

Seed Round in 2018
Nebula Genomics is a biotechnology company founded in 2016 and based in San Francisco, California. It specializes in human genome sequencing and the creation of a marketplace for genomic and health data aimed at consumers, researchers, and the medical community. The company's mission is to facilitate genomic sequencing and enhance personalized medicine by aggregating a substantial repository of genetic information. Utilizing blockchain technology, Nebula Genomics ensures that consumers retain control over their data and receive compensation for its use. The marketplace enables researchers to analyze rich genetic datasets, which can accelerate drug development and improve the efficiency of clinical trials. Founded by prominent genomics researcher George Church and his associates, Nebula Genomics offers advanced DNA sequencing technology that allows clients to explore all genes and genetic variants in the genome, thereby providing comprehensive insights into individual health.

Orchard Therapeutics

Series B in 2017
Orchard Therapeutics is a UK-based biopharmaceutical company dedicated to developing and commercializing innovative gene therapies for rare diseases. Its core focus is autologous ex vivo gene therapy, transforming hematopoietic stem cells into a gene-modified drug product for single-administration treatments. The company's portfolio includes Strimvelis, approved by the EMA in 2016, and several programs in advanced registrational studies across various disease areas.

Orient Speech Therapy

Series B in 2017
Orient Speech Therapy Center specializes in providing professional speech and language therapy services for children facing communication challenges, including those with autism or speech disorders. The center focuses on the early screening, clinical diagnosis, and therapeutic interventions essential for improving children's speech and social skills. It offers a range of refined curricula designed specifically for young learners, including the Star Curriculum, phonics and oral muscle courses, expression courses, and exercise classes. Through these structured programs, Orient Speech Therapy Center aims to enhance the communicative abilities of children, enabling them to express themselves more effectively and engage socially.

Devoted Health

Series A in 2017
Founded in 2017, Devoted Health is dedicated to enhancing the health and well-being of older Americans by offering integrated Medicare Advantage plans. They provide personalized care through a combination of local providers, virtual and in-home care, dedicated guides, and advanced technology.

Stride Health

Series B in 2017
Stride Health, Inc. is a health benefits platform that specializes in providing affordable health coverage options for independent workers and part-time employees in the United States. The company offers a range of services, including dental plans, doctor and prescription insurance plans, and various health coverage options tailored to meet the needs of its customers. Stride Health simplifies the enrollment process by guiding users through selecting the most cost-effective health plans, aiming to optimize their tax benefits and enhance their take-home pay. Founded in 2013 and based in San Francisco, California, the company was previously known as Covered, Inc. and rebranded to Stride Health, Inc. in March 2013. Stride Health also provides personal advisory services to assist clients in navigating the complexities of their health insurance options.

Apellis Pharmaceuticals

Series E in 2017
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutic compounds through inhibiting the complement system for treating autoimmune and inflammatory diseases. Its lead product candidate, pegcetacoplan, is in Phase III trials for geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, among other indications.

Buoy Health

Series A in 2017
Buoy Health is a health technology company that develops AI-powered digital health tools to help individuals manage healthcare options. It offers an online healthcare assistant that analyzes symptoms, performs first-line triage, and provides treatment recommendations. Its platform delivers real-time symptom analysis and helps users navigate the healthcare system, research benefits, and locate in-network providers. For employers, the platform surfaces benefits information, guides employees to in-network providers, and integrates with other health portals. Founded in 2014 and based in Boston, Buoy Health aims to resemble a physician-patient conversation through machine learning and proprietary data, enabling users to make informed care decisions.

Indalo Therapeutics

Venture Round in 2017
Indalo Therapeutics is a preclinical-stage biotechnology company focused on developing innovative therapies for patients affected by fibrotic diseases. The company is built on significant scientific advancements and aims to address critical unmet medical needs in the fibrosis domain. By leveraging advanced understanding of the molecular mechanisms behind abnormal scarring, Indalo Therapeutics seeks to create treatments that can halt or even reverse fibrosis. The organization is comprised of a skilled team of pharmaceutical scientists and executives, dedicated to improving patient outcomes through novel therapeutic approaches.

Pulmocide

Series B in 2017
Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Celes Care

Seed Round in 2017
Celes Care is India's first online health clinic dedicated exclusively to women, based in Hyderabad. The company provides an accessible platform for women to receive healthcare consultations on various topics, including pregnancy care, nutrition, wellness, and general health. Celes Care connects patients with expert female doctors within a minute, ensuring that consultations are not only prompt but also compassionate and tailored to individual needs. By focusing on holistic healthcare, Celes Care aims to empower women with customized guidance in a supportive environment, making quality healthcare more affordable and convenient.

Abelian Therapeutics

Seed Round in 2017
Abelian Therapeutics is a biotechnology company which engages in harnessing factors in brain disease.

Iora Health

Series D in 2016
Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Orchard Therapeutics

Series A in 2016
Orchard Therapeutics is a UK-based biopharmaceutical company dedicated to developing and commercializing innovative gene therapies for rare diseases. Its core focus is autologous ex vivo gene therapy, transforming hematopoietic stem cells into a gene-modified drug product for single-administration treatments. The company's portfolio includes Strimvelis, approved by the EMA in 2016, and several programs in advanced registrational studies across various disease areas.

PatientPing

Series A in 2015
PatientPing, Inc. is a health technology company that has developed a national care coordination network aimed at enhancing communication among healthcare providers. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers real-time notifications and care guidelines to various healthcare professionals, including physicians, nurses, case managers, and care coordinators. This network spans hospitals, emergency departments, accountable care organizations, physician practices, skilled nursing facilities, home health agencies, and payers. PatientPing's platform includes a tool called Spotlights, which leverages real-time data to analyze utilization and performance trends in patient care. By improving information sharing among care teams, PatientPing facilitates higher quality, cost-effective care, ultimately aiming to enhance patient outcomes and experiences. The company also maintains a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC.

Kyruus

Series C in 2015
Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Cogent Biosciences

Series B in 2015
Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

VitalWare

Series A in 2015
VitalWare, LLC is a provider of revenue cycle software-as-a-service (SaaS) solutions tailored for healthcare organizations. Established in 2011 and based in Yakima, Washington, the company offers a comprehensive suite of products designed to enhance efficiency in documentation, coding, billing, and auditing processes. Key offerings include VitalCDM, which streamlines hospital chargemaster management; VitalCDI, a tool that enhances clinical documentation; and VitalIntelligence, which assists with regulatory compliance. Additionally, VitalWare provides professional services that support healthcare providers in coding guidance, process improvement, and financial impact analysis. With a client base of over 590 healthcare institutions, VitalWare aims to help its partners achieve optimal reimbursement and maintain a healthier revenue cycle through innovative cloud-based technologies and expert regulatory content.

Stride Health

Series A in 2015
Stride Health, Inc. is a health benefits platform that specializes in providing affordable health coverage options for independent workers and part-time employees in the United States. The company offers a range of services, including dental plans, doctor and prescription insurance plans, and various health coverage options tailored to meet the needs of its customers. Stride Health simplifies the enrollment process by guiding users through selecting the most cost-effective health plans, aiming to optimize their tax benefits and enhance their take-home pay. Founded in 2013 and based in San Francisco, California, the company was previously known as Covered, Inc. and rebranded to Stride Health, Inc. in March 2013. Stride Health also provides personal advisory services to assist clients in navigating the complexities of their health insurance options.

Precision BioSciences

Series A in 2015
Precision BioSciences, founded in 2006, is a biotechnology company headquartered in Durham, North Carolina. It specializes in genome editing, developing therapeutic products using its proprietary ARCUS technology. The company focuses on creating allogeneic CAR T immunotherapies to treat cancers like acute lymphoblastic leukemia and non-hodgkin lymphoma, as well as genetic disorders.

Iora Health

Series C in 2015
Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Stride Health

Seed Round in 2015
Stride Health, Inc. is a health benefits platform that specializes in providing affordable health coverage options for independent workers and part-time employees in the United States. The company offers a range of services, including dental plans, doctor and prescription insurance plans, and various health coverage options tailored to meet the needs of its customers. Stride Health simplifies the enrollment process by guiding users through selecting the most cost-effective health plans, aiming to optimize their tax benefits and enhance their take-home pay. Founded in 2013 and based in San Francisco, California, the company was previously known as Covered, Inc. and rebranded to Stride Health, Inc. in March 2013. Stride Health also provides personal advisory services to assist clients in navigating the complexities of their health insurance options.

Orient Speech Therapy

Series A in 2015
Orient Speech Therapy Center specializes in providing professional speech and language therapy services for children facing communication challenges, including those with autism or speech disorders. The center focuses on the early screening, clinical diagnosis, and therapeutic interventions essential for improving children's speech and social skills. It offers a range of refined curricula designed specifically for young learners, including the Star Curriculum, phonics and oral muscle courses, expression courses, and exercise classes. Through these structured programs, Orient Speech Therapy Center aims to enhance the communicative abilities of children, enabling them to express themselves more effectively and engage socially.

Cogent Biosciences

Series A in 2014
Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Pulmocide

Series A in 2013
Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Iora Health

Series B in 2013
Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Kyruus

Series B in 2013
Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Lumere

Seed Round in 2012
Lumere, Inc. is a Chicago-based company that offers a cloud-based platform designed to assist hospitals and physicians in reducing clinical variation and unnecessary costs associated with medical devices and pharmaceuticals. The platform features tools such as Product Introduction Management, which redefines the device vetting process through analysis of clinical evidence and best practices; Category Optimization, which integrates clinical insights with data from health systems to identify potential cost savings; and Variation Management, which analyzes procedural utilization data to evaluate how medical devices are used. Additionally, Utilization Management combines clinical information with prescriber patterns to optimize drug spending and address inappropriate usage. Lumere also provides physician advisory services to ensure alignment between healthcare providers and hospital management. Founded in 2012, Lumere was previously known as Procured, Inc., and operates as a subsidiary of Global Healthcare Exchange, LLC.

Iora Health

Venture Round in 2011
Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Hile

Venture Round in 2010
Hile is a manufacturer of veterinary biological products based in Shanghai, specializing in the production of animal vaccines. The company offers a diverse range of over 40 categories of products for poultry, livestock, and pets. Hile focuses on preventing livestock diseases, enhancing the health of animals, and improving production efficiency for farmers. In addition to its product offerings, Hile provides comprehensive solutions and access to a network of veterinary experts, ensuring that clients receive authoritative support in managing animal health.

Ironwood Pharmaceuticals

Series C in 2002
Ironwood Pharmaceuticals is a specialty pharmaceutical company focused on gastroenterology therapies. Its lead product is linaclotide, marketed as LINZESS in the United States and CONSTELLA elsewhere, for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. The company is advancing other GI candidates, including MD-7246, an oral non-opioid pain reliever for abdominal GI pain, and IW 3718, a gastric-retentive bile acid sequestrant in Phase III for GERD. Ironwood pursues collaborations to expand linaclotide’s reach in North America, China, Hong Kong, Macau, and Japan, with agreements involving Allergan and AstraZeneca and a license with Astellas for Japan. It operates an independent subsidiary, Microbia, that develops bioprocesses for pharmaceuticals and related industries. Founded in 1998, Ironwood is headquartered in Massachusetts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.